Drugs / ARV-766
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05067140 | Sep 2021 → May 2027 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARV-766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05067140 ↗ |
| Route | Oral | “Part B: Oral tablet(s) once daily in 28 day cycles.” NCT05067140 ↗ |